MDM2 and CDK4 amplification is a potential therapeutic target in these tumours with ongoing Phase I and II trials of CDK4 and/or MDM2 inhibitors, but there are no established treatment options developed yet based on these genetic alterations [9]. Here, CDK4 is linked to neoplasm.